Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
3.45% $25.52
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2 034.44 mill |
EPS: | -2.91 |
P/E: | -8.77 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 79.72 mill |
Avg Daily Volume: | 1.220 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -8.77 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.49x |
Company: PE -8.77 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-5.46 (-121.39%) $-30.98 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 24.10 - 26.94 ( +/- 5.58%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-19 | Levin Arthur A | Sell | 5 000 | Stock Option (Right to Buy) |
2024-03-19 | Levin Arthur A | Buy | 5 000 | Common Stock |
2024-03-19 | Levin Arthur A | Sell | 5 000 | Common Stock |
2024-03-13 | Maclean Michael F | Sell | 40 000 | Stock Option (Right to Buy) |
2024-03-13 | Maclean Michael F | Buy | 40 000 | Common Stock |
INSIDER POWER |
---|
28.00 |
Last 100 transactions |
Buy: 3 176 200 | Sell: 1 537 152 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $25.52 (3.45% ) |
Volume | 1.195 mill |
Avg. Vol. | 1.220 mill |
% of Avg. Vol | 97.94 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $12.50 | N/A | Active |
---|
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.